The TET2 c.4164_4167del (p.Met1388IlefsTer59; p.M1388Ifs*59) variant has not been reported in ClinVar.¹ This variant is absent from gnomAD v2.1 and gnomAD v4.1, placing it below the 0.1% rarity threshold used for PM2 in non-VCEP review.² Published TET2 studies identified through curated review show that leukemia-associated TET2 alterations impair 5-hydroxymethylcytosine generation, and structural work supports the functional importance of the C-terminal catalytic region, which is consistent with loss of function as a disease-relevant mechanism for truncating variants.³ SpliceAI predicts no significant additional splice effect for this deletion, with a maximum delta score of 0.00; REVEL and BayesDel are not available for this variant type.⁴